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In murine bone marrow macrophages, lipopolysac-
charide (LPS) induces apoptosis through the autocrine
production of tumor necrosis factor- (TNF-), as dem-
onstrated by the fact that macrophages from TNF- re-
ceptor I knock-out mice did not undergo early apoptosis.
In these conditions LPS up-regulated the two concen-
trative high affinity nucleoside transporters here shown
to be expressed in murine bone marrow macrophages,
concentrative nucleoside transporter (CNT) 1 and 2, in a
rapid manner that is nevertheless consistent with the de
novo synthesis of carrier proteins. This effect was not
dependent on the presence of macrophage colony-stim-
ulating factor, although LPS blocked the macrophage
colony-stimulating factor-mediated up-regulation of the
equilibrative nucleoside transport system es. TNF-
mimicked the regulatory response of nucleoside trans-
porters triggered by LPS, but macrophages isolated
from TNF- receptor I knock-out mice similarly up-reg-
ulated nucleoside transport after LPS treatment. Al-
though NO is produced by macrophages after LPS treat-
ment, NO is not involved in these regulatory responses
because LPS up-regulated CNT1 and CNT2 transport
activity and expression in macrophages from inducible
nitric oxide synthase and cationic amino acid trans-
porter (CAT) 2 knock-out mice, both of which lack in-
ducible nitric oxide synthesis. These data indicate that
the early proapoptotic responses of macrophages, in-
volving the up-regulation of CNT transporters, follow
redundant regulatory pathways in which TNF--
dependent- and -independent mechanisms are involved.
These observations also support a role for CNT trans-
porters in determining extracellular nucleoside avail-
ability and modulating macrophage apoptosis.
Macrophages play a key role in the pathogenesis of endotoxic
shock by synthesizing NO and TNF-1 (1–4), which induce
apoptosis in a variety of cell types, including macrophages
themselves (1, 2, 4–6). Macrophage activation and apoptosis
appear to be modulated by extracellular nucleosides and nu-
cleotides (7–12). These effects are partially explained by their
interaction with adenosine and P2 receptors, respectively. Al-
though high concentrations of adenosine seem to favor apopto-
sis in a variety of cell types, including leukemia cells, endothe-
lial cells, smooth muscle cells, and cells from the central
nervous system (13–18), adenosine receptor agonists, when
added to the macrophage cell line RAW264.7, inhibit the LPS-
induced production of TNF- and NO (19). The effect on TNF-
production appears to be exerted at the transcriptional level
and is partly specific because it does not modify the production
of other cytokines such as interleukin-6 and interleukin-8 (8).
In primary cultures of murine bone marrow macrophages,
adenosine, through its interaction with A2B receptors, blocks
the IFN--induced expression of inducible nitric oxide synthase
(iNOS) and TNF- (20). However, the expression of this specific
receptor is also up-regulated by IFN-, thus contributing to a
feedback mechanism for the fine tuning of macrophage activa-
tion/deactivation processes (20). A similar complex network
may also apply to the actions of nucleotides. ATP can also block
the release of TNF- from macrophages activated by LPS and
IFN- (7, 9–11, 21). Nevertheless, these two agents also up-
regulate the synthesis of the P2Z/P2X7 receptor for ATP (22),
which is again consistent with the idea of feedback mechanisms
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contributing to deactivation in macrophages.
The actions of extracellular nucleotides may be partially
mediated by their catabolites, which are generated by the ac-
tion of extracellular nucleotidases and lead to the synthesis of
adenosine. Similarly, adenosine catabolites such as inosine
may mimic some of the effects of this nucleoside (23). Although
some of these actions may require the extracellular presence of
nucleosides, others appear to involve uptake into the cell (12,
17). Considering that nucleoside transport is necessary either
to generate active metabolites intracellularly or to modulate
adenosine availability to its receptors, nucleoside transporters
may be elements of these regulatory networks, which are key
determinants of macrophage activation during septic shock.
Recently we have characterized the nucleoside transporters
in murine bone marrow macrophages (50). This cell type basi-
cally expresses an es-type nucleoside transport system, which
presumably corresponds to the expression of the murine ENT1
gene, and two concentrative nucleoside transporters of the cit
and cib type, which are the result of the co-expression of the
pyrimidine- and purine-preferring transporters CNT1 and
CNT2. Most of the kinetic and molecular properties of these
and other nucleoside transporters cloned so far have recently
been reviewed (24–29). Nucleoside transporter expression is
highly regulated in epithelial cell types, such as hepatocytes, by
cell cycle progression and differentiation (29–31). In murine
bone marrow macrophages, the stimulation of cell proliferation
by MCSF is related to a selective up-regulation of the ENT1
transporter, whereas treatment of these cells with IFN- re-
sults in the inhibition of cell proliferation and ENT1 induction
at a time when this triggers the expression of the two CNT
transporters, CNT1 and CNT2 (50).
On the basis of this evidence, we wondered whether treat-
ment of murine bone marrow macrophages with the proapo-
ptotic agent LPS would modulate nucleoside transporter ex-
pression. If this were the case, it might help us understand how
these plasma membrane proteins contribute to the regulation
of macrophage activation and apoptosis. Essentially, this study
shows that LPS selectively up-regulates the CNT1 and CNT2
transporters. This response is not dependent on the presence of
MCSF, although LPS blocks the up-regulation of the es trans-
port system it triggers. LPS treatment of murine bone marrow
macrophages resulted in the early expression of TNF- and the
subsequent synthesis of iNOS. TNF- triggers early apoptotic
events in these primary cultures because early programmed
cell death is blocked in LPS-treated macrophages isolated from
TNF- receptor I knock-out mice. NO does not appear to be
involved in the up-regulation of CNT transporters because
macrophages isolated from mice lacking inducible NO synthe-
sis (iNOS and CAT2 knock-out mice) still respond to LPS.
However, TNF- was shown to mimic the effects of LPS on
nucleoside transporters. Nevertheless, the evidence that
macrophages isolated from TNF- receptor I knock-out mice
still respond to LPS treatment indicates that the early pro-
apoptotic responses of macrophages involving CNT nucleoside
transporters are regulated by redundant pathways in which
TNF--dependent and -independent mechanisms participate.
MATERIALS AND METHODS
Mice, Cells, and Culture Conditions—Bone marrow macrophages
were obtained as described previously (32) from the femurs of 6–10-
week-old BALB/c mice. The ends of the bones were cut, and the marrow
was irrigated with culture medium to obtain a suspension, which was
then passed through an 18-gauge needle to desegregate the cells for
subsequent culture. Cell culture was performed on 150-mm Petri dishes
in 40 ml of high glucose Dulbecco’s modified Eagle’s medium containing
20% fetal calf serum (Sigma) and 30% L cell-conditioned medium as a
source of MCSF. Dishes were cultured at 37 °C in a humidified 5% CO2
atmosphere until confluence for 7–8 days. These cultures turned out to
be fully differentiated homogeneous populations of adherent macro-
phages suitable for further experiments in which cells were either
cultured in the same medium or starved of MCSF by keeping them in
Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bo-
FIG. 1. Effect of LPS treatment on
cell number, DNA fragmentation,
and radiolabeled nucleoside incorpo-
ration into DNA and RNA. Murine
bone marrow macrophages growing in the
presence of MCSF were treated with LPS
(100 ng/ml), and DNA fragmentation (a)
and cell number (b) were assessed at the
indicated times of treatment. Solid bars
correspond to LPS-treated macrophages,
whereas open bars depict data obtained in
cell cultures in the absence of LPS. The
role of TNF- in macrophage apoptosis
was analyzed in cells isolated either from
wild type (c) or from TNF- receptor I
knock-out mice (d) cultured in the pres-
ence of either LPS (solid bars), TNF-
(open bars), or phosphate-buffered saline
as control (dashed bars). DNA fragmenta-
tion was measured 6 h after treatments.
Tritiated thymidine and uridine incorpo-
ration into nucleic acids was also as-
sessed. The first measurement corre-
sponds to incorporation into DNA (e),
whereas the second parameter is essen-
tially a measurement of nucleoside incor-
poration into RNA (f). Open bars corre-
spond to cells cultured in the absence of
LPS, whereas solid bars correspond to
LPS-treated macrophages. All these ob-
servations are the mean  S.E. of tripli-
cate measurements made in at least three
independent experiments. AU, absorb-
ance unit.
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vine serum for at least 18 h. In these conditions the cell cycle was
arrested at G0. Cells were then incubated either with or without MCSF
(1200 units/ml) either in the presence or in the absence of LPS (100
ng/ml) for the indicated times (see below). In some experiments, cells
cultured either in the presence or in the absence of MCSF were exposed
to TNF- (100 ng/ml). Recombinant murine TNF- was obtained from
PrepoTech EC (London, UK). LPS was purchased from Sigma and
recombinant murine MCSF from R&D Systems (Minneapolis, MN).
Bone marrow macrophages isolated from three knock-out mouse
strains were also used in this study. iNOS knock-out mice were pur-
chased from The Jackson Laboratory (Bar Harbor, ME). The TNF-
receptor I knock-out mice were generated and characterized as reported
(33). Functional inducible NO knock-out mice generated by disrupting
the arginine transporter CAT2 gene (34) were also used to complement
the data obtained with the iNOS knock-out animals.
Analysis of Apoptosis—Low molecular weight apoptotic DNA, ob-
tained as described previously (4), was measured by an enzyme-linked
immunosorbent assay (ELISA) (Cell Death Detection, ELISA Plus;
Roche Molecular Biochemicals) that is directed against cytoplasmic
histone-associated DNA fragments. Each point was performed in trip-
licate, and the results are expressed as the mean  S. D.
Nucleic Acid Synthesis and Cell Counting—DNA synthesis was
quantified by measuring the incorporation of tritiated thymidine (Am-
ersham Pharmacia Biotech) into DNA as described previously (35). For
this purpose cells were grown on 24-well tissue culture plates in 1 ml of
medium without MCSF for at least 18 h. The cells were then cultured
in the presence of MCSF and, at the desired times, the medium was
removed and replaced by 0.5 ml of the same buffer but containing 1
Ci/ml [3H]thymidine. Cells were incubated for 3 h and then fixed in
70% methanol, washed three times in ice-cold 10% trichloroacetic acid,
and solubilized in 1% SDS and 0.3% NaOH prior to radioactivity count-
ing. RNA synthesis was monitored in a similar way but with tritiated
uridine as substrate. The number of viable cells was assessed by trypan
blue exclusion with a hemocytometer.
Transport Experiments—Transport experiments were performed on
35-mm tissue culture dishes in which macrophages had been seeded
after growing for 7 days in the 150-mm flasks. Uptake measurements
were performed as described previously (31) with minor modifications.
[5,6-3H]uridine (Amersham Pharmacia Biotech) was routinely used as
substrate at a concentration of 1 M. Na-dependent transport was
monitored by determining uridine uptake in either 137 mM NaCl or 137
mM choline chloride uptake medium as described (31). The relative
contribution of the N1 transport system (CNT2-related) to the Na-de-
pendent component of transport was assessed by inhibiting uridine
uptake by saturating concentrations of formycin B, an N2 substrate.
The formycin B-resistant component of the Na-dependent uridine
transport is accounted for by the N2 transport system (CNT1-related).
Three-min incubations were routinely performed because they reflect
linear velocity conditions and provide enough sensitivity for cis-inhibi-
tion analysis. The dishes were washed three times in 2 ml of a cold stop
buffer consisting of 137 mM NaCl and 10 mM HEPES, pH 7.4. Cells were
then incubated with 0.5 ml of 0.5% Triton X-100 to allow disaggrega-
tion, and the resulting extract was used for radioactivity counting and
protein determination following the Bradford technique (Bio-Rad).
RNA Isolation and Northern Blot Analysis—Total RNA (20 g) iso-
lated from macrophages using the Rneasy Mini kit from Qiagen
(Hilden, Germany) was separated in 1% agarose with 20 mM MOPS, 1
mM EDTA, pH 7.4, and 3% formaldehyde buffer. The RNA was trans-
ferred overnight onto an Immobilon filter (Amersham Pharmacia Bio-
tech) and cross-linked by irradiation with UV light. Filters were
treated, prehybridized, and hybridized as described previously (31, 36,
37) using CNT2, ENT1, TNF-, and 18 S cDNAs. The CNT2 and ENT1
probes corresponded to the rat cDNA fragments comprising nucleotides
776–1465 and 5–1375, respectively. Labeled probes were generated by
random priming using [-32P]dCTP and routinely used at 106 cpm/ml.
After high stringency washing (31, 36, 37), filters were exposed, and
films were processed for densitometric analysis.
Loading and transfer controls were routinely used in all the experi-
ments. Loading was assessed by including ethidium bromide in the
samples to be run on the gels, whereas the 18 S RNA was used as a
transfer control, as shown below.
Western Blot Analysis—Cell extracts for Western blot analysis were
obtained after washing the cells twice in cold phosphate-buffered saline
followed by lysis in 1% Nonidet P-40, 10% glycerol, 50 mM HEPES, pH
7.5, and 150 mM NaCl, supplemented with a protease inhibitor mixture
consisting of 1 g/ml aprotinin, 1 g/ml leupeptin, 86 g/ml iodoacet-
amide, and 1 mM phenylmethylsulfonyl fluoride. Protein was deter-
mined following the Bradford technique (Bio-Rad). Protein samples (20
g) were incubated for 6 min at 95 °C prior to 10% SDS-polyacrylamide
gel electrophoresis. Proteins were transferred onto filters (Immo-
bilon-P, Millipore, New Bedford, MA), which were then blocked in a 5%
dry milk-supplemented 0.2% Tween 20, phosphate-buffered saline prior
to immunoreaction. To monitor CNT1 expression, a monospecific rabbit
polyclonal antibody raised against an N terminus fragment (residues
45–67) of the corresponding rat horthologue was used (37, 38). This
antibody specifically cross-reacted with the murine transporter as de-
scribed previously (50). To monitor the expression of iNOS, a commer-
cial rabbit antibody against mouse iNOS (M-19, Santa Cruz Biotech-
nology, Santa Cruz, CA) was used. As a loading and transfer control for
this technique, a mouse anti-mouse -actin antibody (Sigma) was used.
RESULTS
Effect of LPS Treatment on the Proliferation, Nucleic Acid
Synthesis, and DNA Fragmentation of Murine Bone Marrow
Macrophages—Treatment of murine bone marrow macro-
phages with LPS significantly decreased the cell number and
induced the fragmentation of DNA and blockade of thymidine
incorporation into DNA in 6 h (Fig. 1). The early apoptotic
events triggered by LPS were mediated by the autocrine pro-
duction of TNF- by macrophages because cells isolated from
TNF- receptor I knock-out mice were protected from apoptosis
after LPS treatment (Fig. 1). The late phase of apoptosis after
12 h of LPS treatment was shown previously to be NO-depend-
ent (4) and occurs more slowly than the initial one. Both pro-
liferating and apoptosing macrophages required extracellular
nucleosides for RNA synthesis (Fig. 1).
Effect of LPS on the Nucleoside Transporter Activity and
Expression in Murine Bone Marrow Macrophages—Murine
bone marrow macrophages showed at least three nucleoside
transport activities that correspond to the co-expression of the
es-related transporter ENT1 and the Na-dependent trans-
porters N1 (CNT2) and N2 (CNT1). This was assessed not only
by the detection of the biological activity of these systems but
also by the presence of either the mRNA (as for ENT1 and
CNT2) or the protein (as for CNT1) (see Fig. 3). LPS selectively
up-regulated the N1 and N2 transport systems irrespective of
whether the macrophages had been MCSF-starved (Fig. 2).
FIG. 2. Up-regulation of CNT-type nucleoside transport activ-
ity and down-regulation of es transport in LPS-treated macro-
phages. Macrophages were growth-arrested by culturing them for 18 h
in the absence of MCSF. Cells were then induced to proliferate by
MCSF or incubated in the absence of the growth factor for 24 h, either
in the absence (open bars) or in the presence (solid bars) of LPS. At this
point, Na-dependent uridine (1 M) transport activity associated with
N1 and N2 transport systems (CNT2 and CNT1 transporters, respec-
tively), as well as the Na-independent ENT1-related transport activity
es, were measured, as indicated under “Materials and Methods.” Data
are the mean  S.E. of triplicate observations in three independent
experiments. prot, protein.
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This suggests that the up-regulation of the concentrative nu-
cleoside transporters is independent of the proliferative stim-
ulus triggered by MCSF. However, the up-regulation of the es
transport system triggered by MCSF was almost completely
blocked by LPS, thus suggesting that the inhibition of macro-
phage proliferation associated with cell activation and apopto-
sis does not require enhanced es transport activity, although
cell proliferation does, as described previously (50).
The time course of these events is relatively short (Fig. 3).
CNT2 mRNA amounts increased only 3 h after LPS treatment
(Fig. 3, c and d), which suggests that CNT2 is one of the genes
that may switch on during the early phase of LPS-induced
apoptosis of murine bone marrow macrophages. The transient
accumulation of CNT2 mRNA shown in Fig. 3, c and d is
consistent with the transcriptional activation of this gene re-
sulting in de novo synthesis of CNT2 transporters and high
activity of the N1 transport system, as detected 24 h after LPS
treatment (Fig. 2). Similarly, the amounts of CNT1 protein are
significantly higher than control macrophages as early as 6 h
after LPS treatment (Fig. 3, a and b), thus supporting the view
that the two CNT transporters expressed in murine bone mar-
row macrophages are highly responsive to LPS-induced apo-
ptosis and, if these regulatory responses were transcriptionally
mediated, their genes should switch on relatively quickly after
treatment with the lipopolysaccharide. The decrease in es
transport activity found in LPS-treated macrophages in the
presence of MCSF correlated with a progressive decrease in
the ENT1 mRNA that occurred much more slowly than the
changes recorded for the CNT2 mRNA (Fig. 3, c and d), which
suggests that the regulatory response of the equilibrative nu-
cleoside transporter mostly occurs during the second phase of
LPS-induced apoptosis.
FIG. 3. Time course of the effects of
LPS on CNT1 protein and CNT2 and
ENT1 mRNA amounts in macrophages.
Eighteen-h MCSF-starved macrophages
were cultured in the presence of the growth
factor either with or without LPS for the
indicated times. a, the time course of CNT1
protein changes, as measured by Western
blot, after the addition of LPS. The amounts
of -actin protein were also monitored as
loading and transfer control. A representa-
tive experiment is shown. The densitometric
data obtained from three independent ex-
periments are shown in b. Open bars corre-
spond to CNT1, whereas solid bars corre-
spond to the -actin control. c, the changes
observed in CNT2 and ENT1 mRNA levels,
as measured by Northern blot analysis, after
LPS addition, including the 18 S RNA levels
as loading and transfer controls. Similarly,
the densitometric data obtained from four
independent experiments are shown in d
(open bars, CNT2 mRNA; solid bars, ENT1
mRNA; dashed bars, 18 S RNA).
FIG. 4. LPS triggered TNF- expres-
sion and iNOS synthesis in macro-
phages. In the culture conditions indi-
cated in the legend for Fig. 3, the TNF-
mRNA levels and the amount of iNOS
protein were analyzed by Northern and
Western blots at the indicated times after
LPS addition. As in Fig. 3, the 18 S RNA
and the -actin protein were used as con-
trols. A representative experiment is
shown; similar observations were ob-
tained in three independent experiments.
FIG. 5. TNF- mimicked the effects of
LPS on CNT and ENT expression and
related transport activities. a, macro-
phages were again growth-arrested by cul-
turing them for 18 h in the absence of
MCSF, as described in the legend for Fig. 2.
Cells were then induced to proliferate by
MCSF or incubated in the absence of the
growth factor for 24 h, either with (solid
bars) or without (open bars) TNF- (100 ng/
ml). At this point, Na-dependent uridine (1
M) transport activity associated with N1
and N2 transport systems (CNT2 and CNT1
transporters, respectively), as well as the
Na-independent ENT1-related transport
activity es, were measured. The amounts of
CNT1 protein (b) and those of CNT2 and
ENT1 mRNA (c) after 24 h of TNF- treat-
ment were also monitored. A representative
experiment is shown, although identical ob-
servations were made in three independent
experiments.
Apoptosis of Macrophages and Nucleoside Transporters30046
Characterization of TNF- and iNOS Production after LPS
Treatment of Murine Bone Marrow Macrophages—LPS rapidly
increased the expression of TNF- in macrophages (Fig. 4a). As
previously reported, this is immediately followed by the secre-
tion of TNF-, as deduced from the measurement of this cyto-
kine in supernatants from LPS-treated macrophages (4). How-
ever, iNOS synthesis takes longer to occur, which is in
agreement with its role during the second phase of the LPS-
induced apoptosis (Fig. 4b). In fact, the iNOS protein was not
detected 2 h after LPS treatment, which in principle would rule
out a putative role for NO in the regulatory responses of the
concentrative nucleoside transporters because the two CNT
proteins appear to be up-regulated before iNOS synthesis
occurs.
Role of TNF- in the LPS-mediated Regulation of Nucleoside
Transporters in Murine Bone Marrow Macrophages—The im-
mediate autocrine production of TNF- by LPS-stimulated
macrophages suggests that this cytokine is involved in the
regulatory responses of nucleoside transporters during the
early phase of LPS-induced apoptosis. Thus, the activity of
the three macrophage nucleoside transport systems was meas-
ured after treatment of the cells with TNF- either in the
presence or in the absence of MCSF. TNF- alone mimicked the
LPS-induced changes in the activity of nucleoside transport
systems N1, N2, and es (Fig. 5a). In fact, TNF- blocked the
up-regulation of the es transport system triggered by MCSF.
TNF- also increased the amounts of CNT1 protein (Fig. 5b)
and the expression of CNT2 mRNA (Fig. 5c). In contrast, ENT1
mRNA amounts decreased (Fig. 5d). These observations, taken
together, would suggest that TNF- may be the only mediator
of the LPS-induced effects on nucleoside transporter expres-
sion. To test this hypothesis, similar experiments were per-
formed using bone marrow macrophages derived from TNF-
receptor I knock-out mice (Fig. 6a). As previously reported (4),
the type I p55 TNF- receptor is solely responsible for TNF--
induced apoptosis in macrophages. In fact, the early apoptotic
events triggered by the autocrine production of this cytokine
are completely blocked in LPS-stimulated macrophages from
TNF- receptor I knock-out mice. Interestingly, the regulatory
responses of nucleoside transport systems N1, N2, and es were
unchanged in LPS-treated macrophages (Fig. 6a), which rules
out the idea that TNF- is the only mediator of the action of
LPS on nucleoside transport performance. Although iNOS is
unlikely to be involved in the up-regulation of CNT-related
transport systems because there is a lack of concordance be-
tween the time course of their up-regulation, it was possible
that NO could be involved in the slow down-regulation of the es
transport system. Thus, the response of these transport sys-
tems to LPS was also investigated in bone marrow macro-
phages derived from iNOS knock-out mice. No changes in the
up-regulation of N1 and N2 transport systems were observed in
the iNOS/ macrophages after exposure to LPS nor was the
decrease in es transport activity affected (Fig. 6b). Similar
results were obtained in macrophages derived from CAT2
knock-out mice (not shown).
DISCUSSION
Although LPS is an activator of macrophages that induces
the secretion of several cytokines (including TNF-, interleu-
kin-1, and interleukin-6), it is also a potent apoptotic agent (4).
This activity occurs mostly in the early phase of interaction
with LPS and after the release of TNF-. In fact, macrophages
synthesize and secrete proinflammatory cytokines during sep-
tic shock (4, 39, 40), and thus treatment of primary cultures of
murine bone marrow macrophages with LPS results in a two-
step process leading to apoptosis, triggered initially by the
autocrine production of TNF- and followed by the generation
of NO as a consequence of the de novo synthesis of iNOS (Ref.
4; this study).
Nucleosides, and particularly adenosine, can inhibit TNF-
and NO synthesis in LPS-stimulated and IFN--induced
macrophages (7–12, 19) by mechanisms that rely, at least par-
tially, upon the interaction of adenosine with membrane recep-
tors. The long term control of these regulatory interactions
appears to involve receptor synthesis and insertion into the
plasma membrane of the activated macrophage, as suggested
by evidence that IFN- can up-regulate the synthesis of aden-
osine receptors of the A2B type (20). This sort of feedback
regulatory mechanism may also apply to ATP and P2 receptors,
as indicated above (7, 9–11, 21, 22).
This study demonstrates that LPS-induced macrophages dif-
ferentially regulate nucleoside transporter activity and expres-
sion and that this occurs in two steps; rapid up-regulation of
the nucleoside transporters of CNT type N1 and N2 is followed
by a slower decrease in ENT1 expression, thus resulting in low
es transport activity. The inhibition of es transport activity and
ENT1 mRNA levels by LPS is evident only when macrophages
are actively proliferating in the presence of MCSF, which fur-
ther supports the recently described role of the ENT1 trans-
porter in macrophage proliferation and DNA synthesis (50).
Consequently, the blocking of MCSF-induced proliferation re-
sults in es down-regulation.
In general terms CNT-type transporters show a much higher
affinity for nucleosides than the equilibrative ENT-type carri-
ers (24–26). In addition, it has recently been shown that cells
with high endogenous equilibrative transport activities can be
FIG. 6. Evidence for TNF- and iNOS-independent mechanisms mediating the regulatory responses of nucleoside transport
systems to LPS in macrophages. N1, N2, and es nucleoside transport activities were measured in macrophages that had been starved for 18 h
in the absence of MCSF and then incubated for a further 24 h in the presence of the growth factor, either with (solid bars) or without (open bars)
LPS. To determine whether TNF- and/or iNOS mediate the effects of LPS on these transport systems, macrophages used in these experiments
were obtained from knock-out mice lacking the p55 receptor for TNF- (TNF--RI-KO) or iNOS (iNOS-KO). Data are the mean  S.E. of triplicate
observations in three independent experiments. RI, receptor I; prot, protein.
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highly sensitized to nucleoside-derived cytotoxic drugs simply
by heterologously expressing a CNT isoform, irrespective of
whether they were also substrates for the ENT carriers already
expressed (41). Moreover, it is well established that high affin-
ity neurotransmitter transporters are involved in the modula-
tion of neurotransmitter availability to receptors in synaptic
transmission (42, 43), which further supports the view that
high affinity transporters are better regulators of agonist avail-
ability than low affinity carriers. This is consistent with the
need of very low concentrations of agonists to induce the recep-
tor-mediated responses, which may be much lower than most
reported apparent Km values of other transporters with similar
substrate specificities but are not involved in synapsis. If CNT
transporters determine adenosine availability to those recep-
tors expressed in macrophages, the up-regulation of CNT
transporter expression and activity by either LPS or IFN- may
contribute to the feedback mechanisms that determine the
complex regulatory network of activation/deactivation and
apoptosis pathways in macrophages. This is consistent with the
consideration of the two CNT genes as “early response” genes
during LPS-induced apoptosis. The possibility that up-regula-
tion of nucleoside transporters also affects the intracellular
nucleoside/nucleotide pool in a way that may modulate the
apoptotic response of macrophages should not be ruled out and
requires further research.
The evidence that CNT transporters are involved in the early
apoptotic events in LPS-induced macrophages also suggests
that they are putative targets in anti-inflammatory therapy.
Although no effective irreversible inhibitors have been de-
scribed for the CNT-type transporters, these carriers have
broad substrate specificity, as demonstrated when analyzing
the routes for the cell uptake of nucleoside derivatives used in
antiviral and anticancer therapy (44–46). This suggests that
the transporter tolerance of chemical modification of the natu-
ral substrates may ultimately result in the design of suitable
transporter inhibitors of pharmacological interest.
This study has also addressed the role of TNF- and NO as
mediators of the effects of LPS on CNT and ENT transporters.
NO was initially a poor candidate for mediating LPS action
based upon the time course of CNT induction and that of iNOS
synthesis (Ref. 4; this study). Nevertheless, NO could play a
role in the longer term down-regulation of ENT1, as demon-
strated in B cells (47). This is not the case according to the
results obtained using the iNOS and CAT2 knock-out macro-
phages. The possibility that TNF- mediates the phorbol 12-
myristate 13-acetate-induced up-regulation of N-type trans-
porters in human B cells was indicated by the finding that it
could increase the concentrative nucleoside transport activity
in Raji cells (36). However, from this study it appears that,
although TNF- may contribute to the LPS-induced early
apoptotic events that lead to the up-regulation of the CNT-
transporters, this cytokine is not required for this specific ac-
tion because macrophages from TNF- receptor I knock-out
mice still respond to LPS treatment by increasing CNT1 and
CNT2 transporter activity and expression, although activation
of p55 type I TNF- receptor is necessary and sufficient for
apoptosis in a variety of cell types (4–6, 48, 49).
In summary, this study shows that LPS-induced apoptosis of
murine bone marrow macrophages is characterized by a rapid
increase in the concentrative nucleoside high affinity transport
systems N1 and N2, a feature that is consistent with the de
novo synthesis of CNT1 and CNT2 carrier proteins. This reg-
ulatory response occurs during a TNF--dependent early phase
of LPS-induced apoptosis in macrophages, but although TNF-
by itself can also up-regulate CNT transporters and thus may
be considered as a mediator of LPS action, a TNF--independ-
ent pathway could also be involved. Work is in progress to
elucidate the TNF--independent pathway of LPS activation of
concentrative nucleoside transporters. These data, together
with previous observations linking nucleoside and nucleotide
receptors with cytokine production by macrophages, suggest
that nucleoside transporters are also elements of this complex
regulatory network that determines macrophage activation/
deactivation and apoptosis processes.
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